EyePoint Pharmaceuticals Inc (EYPT)
EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
EYPT SEC Filing Email Alerts Service
| Company Name: |
EyePoint Pharmaceuticals Inc |
| Website: |
www.eyepointpharma.com |
| Sector: |
Drugs & Pharmaceuticals |
| Number of ETFs Holding EYPT: |
21 |
| Total Market Value Held by ETFs: |
$78.16M |
| Total Market Capitalization: |
$1.09B |
| % of Market Cap. Held by ETFs: |
7.18% |
|
|
April 19, 2024 • 8:50 AM Eastern
Strong Buy (4.00 out of 4)
100th percentile
|
|
Free EYPT Email Alerts:
